Michael S. Weiss founded and has served as the Company’s Executive Chairman, President and CEO since December 2011. Prior to founding TG, Weiss founded and was the CEO of ACCESS Oncology (1999) that merged with Keryx Biopharmaceuticals (2004) for which he served as Chairman and CEO until mid-2009. During his tenure Weiss acquired and developed AURYXIA, which is now approved for the treatment of patients on dialysis. Prior to that Mr. Weiss spent several years as a lawyer and then investor in biotech venture capital prior to founding ACCESS Oncology. Mr. Weiss continues to have a passion for helping early stage biotech companies and serves as Vice Chairman of Fortress Biotech and Chairman of Checkpoint Therapeutics and Mustang Bio. Mr. Weiss is also a biotech investor and founded and serves as Portfolio Manager for Opus Point Partners, a fund that specializes in investing in publicly-traded biotechnology and pharmaceutical companies. Mr. Weiss started his career as a lawyer at Cravath, Swaine and Moore in 1991.